Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Pfizer (NYSE: PFE) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market.